Compare Eaton Corporation plc (ETN) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eaton Corporation plc vs Regeneron Pharmaceuticals Inc — how do they compare? Eaton Corporation plc trades at $429.65 (market cap $164.88B), while Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B). The key difference: Eaton Corporation plc is far larger — about 2.2× Regeneron Pharmaceuticals Inc's market cap, and Eaton Corporation plc pays the higher dividend (1.04%). Which is the better fit depends on your goals — on Pluang, investors hold Eaton Corporation plc for 31 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| ETN | REGN | |
|---|---|---|
Market Cap | $164.88B | $76.14B |
Volume | 2,535,086 | 500,239 |
Sector | Industrials | Health |
52-Week High | $459.96 | $852.03 |
52-Week Low | $315.82 | $557.73 |
Typical Hold Time | 31 Days | 107 Days |
Enterprise Value | $185.51B | $70.85B |
Dividend Yield | 1.04% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eaton Corporation (ETN) trades at $424.51, down 1.58% on the day, amid a near-term bearish technical signal. The company demonstrates strong fundamental health with consistent earnings beats in recent quarters, a 12.75% net income margin, and robust revenue growth, reaching $30.0B in 2026. Recent strategic acquisitions, such as the COL Group announced on September 25, 2026, aim to expand its footprint in high-growth data center and utility markets.
The outlook is supported by a unanimous bullish analyst consensus with a $502.38 price target, though risks include a high P/E ratio of 43.23 and significant capital expenditure reflected in the 2026 investing cash flow of -$12.3B. The stock's near-term performance hinges on the upcoming Q3 2026 earnings result against a $3.53 EPS expectation.
Regeneron Pharmaceuticals (REGN) trades at $739.57, down 0.34% on the day, with a bearish technical signal from moving averages. The company maintains strong fundamentals, including a 27.86% net income margin and consistent earnings beats. Recent news highlights a significant immunology alliance expansion with Sanofi, valued up to $8 billion, which could drive future growth. Cash flow improved in 2025, with net cash flow turning positive at $634.70 million.
The outlook is positive, supported by robust profitability and strategic collaborations, but faces risks from competition in key drug markets and reliance on pipeline success. Analysts are bullish with a consensus price target of $849.84, implying potential upside. Investors should weigh strong financials against execution risks in drug development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
